Search Results - Paul Workman

Refine Results
  1. 1
    Inhibitors of the heat shock response: Biology and pharmacology

    Inhibitors of the heat shock response: Biology and pharmacology by Marissa Powers, Paul Workman

    Published 2007
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors

    Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors by Marissa Powers, Paul Workman

    Published 2006
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Critical parameters in targeted drug development: the pharmacological audit trail

    Critical parameters in targeted drug development: the pharmacological audit trail by Udai Banerji, Paul Workman

    Published 2016
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

    Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? by Len Neckers, Paul Workman

    Published 2012
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Targeting CDC37: An alternative, kinase-directed strategy for disruption of oncogenic chaperoning

    Targeting CDC37: An alternative, kinase-directed strategy for disruption of oncogenic chaperoning by Jennifer R. Smith, Paul Workman

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Drugging cancer genomes

    Drugging cancer genomes by Paul Workman, Bissan Al‐Lazikani

    Published 2013
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    The era of high-quality chemical probes

    The era of high-quality chemical probes by Marco P. Licciardello, Paul Workman

    Published 2022
    Get full text Get full text
    Editorial
    Save to List
    Saved in:
  8. 8
    Death by chaperone: HSP90, HSP70 or both?

    Death by chaperone: HSP90, HSP70 or both? by Marissa Powers, Paul A. Clarke, Paul Workman

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells

    E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells by Rahul S. Samant, Paul A. Clarke, Paul Workman

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis

    Dual Targeting of HSC70 and HSP72 Inhibits HSP90 Function and Induces Tumor-Specific Apoptosis by Marissa Powers, Paul A. Clarke, Paul Workman

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Structure-based drug design: aiming for a perfect fit

    Structure-based drug design: aiming for a perfect fit by Rob L. M. van Montfort, Paul Workman

    Published 2017
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  12. 12
    Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines

    Examination by laser scanning confocal fluorescence imaging microscopy of the subcellular localisation of anthracyclines in parent and multidrug resistant cell lines by HM Coley, WB Amos, PR Twentyman, Paul Workman

    Published 1993
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Silencing of HSP90 Cochaperone AHA1 Expression Decreases Client Protein Activation and Increases Cellular Sensitivity to the HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin

    Silencing of HSP90 Cochaperone AHA1 Expression Decreases Client Protein Activation and Increases Cellular Sensitivity to the HSP90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin by Joanna L. Holmes, Swee Y. Sharp, Steve Hobbs, Paul Workman

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    <i>BRAF</i> and <i>NRAS</i> mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

    <i>BRAF</i> and <i>NRAS</i> mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors by Udai Banerji, Annette Affolter, Ian Judson, Richard Marais, Paul Workman

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Polypharmacology in Precision Oncology: Current Applications and Future Prospects

    Polypharmacology in Precision Oncology: Current Applications and Future Prospects by Albert A. Antolín, Paul Workman, Jordi Mestres, Bissan Al‐Lazikani

    Published 2016
    Get full text
    Revisão
    Save to List
    Saved in:
  16. 16
    Inhibitors of cyclin-dependent kinases as cancer therapeutics

    Inhibitors of cyclin-dependent kinases as cancer therapeutics by Steven R. Whittaker, Aurélie Mallinger, Paul Workman, Paul A. Clarke

    Published 2017
    Get full text
    Revisão
    Save to List
    Saved in:
  17. 17
    Drugging PI3K in cancer: refining targets and therapeutic strategies

    Drugging PI3K in cancer: refining targets and therapeutic strategies by Timothy A. Yap, Lynn Bjerke, Paul A. Clarke, Paul Workman

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  18. 18
    Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors

    Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors by Jennifer R. Smith, Paul A. Clarke, Emmanuel de Billy, Paul Workman

    Published 2008
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    The Cyclin-dependent Kinase Inhibitor CYC202 (<b> <i>R</i> </b>-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-activated Protein Kinase Pathway

    The Cyclin-dependent Kinase Inhibitor CYC202 (<b> <i>R</i> </b>-Roscovitine) Inhibits Retinoblastoma Protein Phosphorylation, Causes Loss of Cyclin D1, and Activates the Mitogen-ac... by Steven R. Whittaker, Mike I. Walton, Michelle D. Garrett, Paul Workman

    Published 2004
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance

    Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance by David González de Castro, Paul A. Clarke, Bissan Al‐Lazikani, Paul Workman

    Published 2012
    Get full text Get full text
    Revisão
    Save to List
    Saved in:

Search Tools: